| Literature DB >> 19551519 |
Steve Novick1, David Christopher, Monisha Dey, Svetlana Lyapustina, Michael Golden, Stefan Leiner, Bruce Wyka, Hans-Joachim Delzeit, Chris Novak, Gregory Larner.
Abstract
This article examines the effects of changing parameters in the test which was proposed by the FDA at the October 2005 Advisory Committee meeting for confirming delivered dose uniformity in orally inhaled and nasal drug products. This article is an extension of the characterization study presented in an accompanying article (Part 1). The goal of this study is to understand how parameters of the test affect the test performance. The effects of changing test parameters such as target interval, maximum allowable proportion in the tail area, and sample size are examined. The results show that changing the maximum allowable tail area and/or the target interval have the largest impact on the test outcomes, i.e., probability of acceptance for a given batch mean and standard deviation. The presented information may provide potential users of the test with a set of tools for optimizing the test characteristics for a particular product.Mesh:
Substances:
Year: 2009 PMID: 19551519 PMCID: PMC2802172 DOI: 10.1208/s12249-009-9269-3
Source DB: PubMed Journal: AAPS PharmSciTech ISSN: 1530-9932 Impact factor: 3.246